227. オスラー病 Osler disease Clinical trials / Disease details
臨床試験数 : 56 / 薬物数 : 72 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04113187 (ClinicalTrials.gov) | June 23, 2020 | 27/9/2019 | Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients | Study of the Efficacy of Propranolol for the Management of Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients | Hereditary Hemorrhagic Telangiectasia;Osler Weber Rendu Disease | Drug: Propranolol treatment;Drug: Placebo | University Hospital, Bordeaux | AMRO-HHT-France - Association Maladie de Rendu-Osler | Completed | 18 Years | N/A | All | 15 | Phase 3 | France |